Tumour-specific CD8 T cells (TST) are often found within solid tumours, but tumours progress despite their presence, suggesting that these TST are dysfunctional 1 . The clinical success of immune checkpoint blockade (for example, PD1/PDL1-and CTLA4-blocking antibodies) and adoptive T cell therapy in a subset of patients with cancer demonstrates the great potential of TST 2 ; however, important questions remain, including how to predict which patients will respond to therapy and precisely which TST mediate clinical responses 3-5 . Moreover, an unmet need is the development of interventions for tumours that are refractory to checkpoint blockade despite having ample TST infiltration.
CD8 T cell chromatin changes during infection
We transferred congenically marked naive (N; CD44 lo CD62L hi ) TCR TAG cells (specific for SV40 large T antigen epitope I (TAG)) 12 from TCR TAG transgenic mice into wild-type C57BL/6 mice, which were immunized one day later with a recombinant Listeria monocytogenes strain expressing TAG (LmTAG) 6, 13 . TCR TAG cells were re-isolated, phenotypically and functionally characterized, and underwent ATACseq and RNA-seq at 5, 7 (effectors; E5, E7) and 60+ days (memory; M) after immunization (Fig. 1a) . N, E5, E7, and M expressed characteristic activation, homing and cytokine receptors (CD44, CD62L, IL7R), transcription factors (TBET), cytotoxic molecules (GZMB, CD107), and pro-inflammatory cytokines (IFNγ , TNFα ) (Extended Data Fig. 1 ).
ATAC-seq libraries generated from N, E5, E7, and M showed the expected distribution of fragment lengths (Extended Data Fig. 2 ). Using DESeq2 (ref. 14) to assess differential chromatin accessibility, we found that substantial chromatin remodelling occurred as cells differentiated from the N to the effector state (E5), with much less remodelling from E5 to E7 and E7 to M (Fig. 1b , c, Extended Data Fig. 3a ). In N, effector gene loci such as Prf1 and Tnf shared highly accessible chromatin and basal transcriptional activity with E5/E7 and M (Extended Data Fig. 3b ), consistent with activating histone marks previously shown at these loci in naive T cells 15, 16 .
We analysed accessibility changes during the N to E5 transition in loci associated with early and late TCR-response genes, as defined by the Immunological Genome Project 17 . Early-response genes showed much fewer changes compared to late-response genes (Extended Data Fig. 3c ). For example, Ldha (encoding LDHA, needed for the metabolic shift to aerobic glycolysis and IFNγ production 18 ) and Mki67 (encoding KI67, required for chromosome segregation during mitosis 19 ) require no change in chromatin accessibility to be rapidly induced after TCR stimulation (Extended Data Fig. 3d ).
Memory T cells exhibit more rapid and robust effector function upon antigen re-encounter compared to naive T cells 20 . K-means clustering of RNA expression patterns (Fig. 1d , left) revealed two trends: transient gene activation or downregulation in E5/E7 but not M (clusters 1, 2, 5, 6), and stable gene activation or downregulation in E5, E7, and M (clusters 3 and 4). In contrast, chromatin accessibility for these loci was largely similar in E5/E7 and M (Fig. 1d, middle) . Thus, the 'effector-like' Tumour-specific CD8 T cells in solid tumours are dysfunctional, allowing tumours to progress. The epigenetic regulation of T cell dysfunction and therapeutic reprogrammability (for example, to immune checkpoint blockade) is not well understood. Here we show that T cells in mouse tumours differentiate through two discrete chromatin states: a plastic dysfunctional state from which T cells can be rescued, and a fixed dysfunctional state in which the cells are resistant to reprogramming. We identified surface markers associated with each chromatin state that distinguished reprogrammable from non-reprogrammable PD1 hi dysfunctional T cells within heterogeneous T cell populations from tumours in mice; these surface markers were also expressed on human PD1 hi tumour-infiltrating CD8 T cells. Our study has important implications for cancer immunotherapy as we define key transcription factors and epigenetic programs underlying T cell dysfunction and surface markers that predict therapeutic reprogrammability.
Chromatin state dynamics of TST dysfunction
We next assessed chromatin-state dynamics in TST over the course of tumorigenesis using the previously described tamoxifen-inducible, autochthonous liver cancer model (AST-Cre-ER T2 ) in which TAG is a tumour-specific antigen 6 . AST-Cre-ER T2 mice initially develop pre-malignant lesions which eventually progress into hepatocellular carcinoma (by day 60-90) 6 . We transferred congenically marked naive TCR TAG cells (N, the same as N in Fig. 1a ) into AST-Cre-ER T2 mice one day before tamoxifen administration and then analysed TCR TAG cells at different time points ( Fig. 2a ). Liver-infiltrating TCR TAG cells downregulated CD62L, uniformly expressed activation markers CD44 and inhibitory receptors PD1 and LAG3, and failed to produce IFNγ or TNFα (Fig. 2b ). Massive chromatin remodelling occurred by day 5, followed by a second wave of remodelling between days 7 and 14 ( Fig. 2c, d , Extended Data Fig. 4a ). Notably, after the second wave, few accessibility changes occurred, even after progression to established tumours at day 60+ ( Fig. 2c-e ). Thus, TST differentiated through two discrete chromatin states: an initial dysfunctional state 1 (L5, L7), and later dysfunctional state 2, established by day 14 and persisting thereafter. Many of the ATAC-seq peaks that were gained or lost were in intronic and intergenic regions (potential enhancer peaks), whereas peaks present in all CD8 T cells were in promoter regions (Extended Data Fig. 4b , bottom); this pattern was also seen in functional CD8 T cell differentiation (Extended Data Fig. 4b, top ).
TCR TAG cells in malignant lesions followed a distinct epigenetic trajectory compared to TCR TAG cells in acute infection (L5 versus E5; Fig. 2d ), and many peak changes were unique to either the early dysfunctional (L5) or functional (E5) state (Extended Data Fig. 4c ) and were found in genes involved in TCR signalling and cytokine production pathways (Extended Data Fig. 4d ). Enhancer peaks in the Ifng locus that opened during normal effector differentiation were inaccessible in dysfunctional TCR TAG cells ( Fig. 2f, right ). An intergenic peak near (− 23.8 kb) the PD1-encoding Pdcd1 locus was uniquely accessible in L5 to L60+ , but not in E5/E7 and M (Fig. 2f , left); a similar peak was described in exhausted T cells in chronic viral infection [21] [22] [23] . We tested whether accessibility of potential transcription factor targets changed preferentially during differentiation from N to L5 as compared to N to E5 (Extended Data Fig. 5a ). Predicted NFATC1-binding sites, including those in genes encoding inhibitory receptors and negative regulators, such as Ctla4, Pdcd1, Tigit, Socs1, and Cblb and transcription factors Egr1 and Egr2, had increased peak accessibility in dysfunctional L5 (Extended Data Fig. 5a, b ). NFAT transcription factor family members, particularly NFATC1 and NFATC2, are important regulators of T cell development and function (reviewed in ref. 24) , as well as exhaustion in chronic viral infections 25 . Although some genes with increased NFATC1 peak accessibility in L5 showed immediate transient transcriptional activation, others were activated later (Extended Data Fig. 5c ). Transcription factor footprints (nucleotide sequences protected from Tn5 transposase-mediated adapter insertion) were detected in accessible motif sites for NFATC1 as well as other transcription factors (Extended Data Fig. 6a ).
Chromatin states correlate with reprogrammability
Notably, the discrete chromatin states in dysfunctional TCR TAG cells correlated temporally with our previous observation that L8 but not L35 were capable of regaining effector function 6 . Indeed, when we re-isolated TCR TAG cells from liver lesions and cultured them in vitro with IL-15 ( Fig. 3a) , previously shown to induce proliferation and restore effector function in tumour-reactive CD8 T cells 26, 27 , L5 and L7 regained the ability to produce IFNγ and TNFα , but TCR TAG cells isolated at day 12 and after did not ( Fig. 3a ). Thus state 1 dysfunction is plastic, but with further chromatin remodelling between days 7 and 14, becomes fixed (state 2).
Chromatin peaks with TCF family motifs closed during the state 1 (L7) to state 2 (L14) transition, whereas E2F, ETS, and KLF family transcription factor motif-containing peaks opened ( Fig. 3b ). Indeed, TCF1 (encoded by Tcf7) protein levels decreased between L7 and L14 (Extended Data Fig. 6b ), and analysis of closing peaks showed enrichment for WNT receptor signalling pathway genes, upstream of TCF family transcription factors, as well as cytokine response, TCR signalling, and T cell differentiation pathway genes (Extended Data Fig. 6c ). Among the TCR signalling genes most upregulated during the L7-L14 transition were negative regulators such as Cish1 and Socs2, whereas co-stimulatory molecule genes such as Icos and Cd28 were downregulated together with closing of multiple peaks within their loci (Extended Data Fig. 6d ).
We next used an in vivo pharmacologic strategy to test the role of NFAT and TCF in TST dysfunction. FK506 is an immunosuppressant that inhibits NFAT nuclear translocation and downstream gene activation 28, 29 , and we used 25% of the full immunosuppression dose to partially downregulate NFAT activity without completely blocking T cell activation and/or effector function. TWS119, a GSK3β inhibitor, enhances differentiation of CD8 T cell to memory cells through WNT/ TCF1 activation 30 , and we therefore treated TCR TAG -adoptively transferred AST-Cre-ER T2 mice with FK506 alone or in combination with TWS119 (Extended Data Fig. 7a ). Indeed, L10 TST from FK506 and FK506/TWS119-treated mice had decreased expression of the NFATC1 targets PD1 and LAG3, increased levels of TCF1 and EOMES (Extended Data Fig. 7b ), and were more efficiently reprogrammable (Extended Data Fig. 7c ) compared to controls or TWS119 alone (data not shown). 
Surface proteins associated with chromatin states
We next looked for cell surface proteins with expression that correlated with chromatin states 1 or 2 and thus might predict reprogrammability of heterogeneous TIL. PD1 and LAG3 were similarly expressed by both plastic (L5, L7) and fixed (L14+ ) dysfunctional TST ( Fig. 2b ) and thus not informative in this regard. We identified membrane protein genes differentially expressed between early (L5, L7) and late (L14 to L60+ ) dysfunctional TCR TAG cells ( Fig. 3c ) and found several markers not previously associated with tumour-induced T cell dysfunction. State 1 (L5, L7) TCR TAG cells had low expression of CD38, CD101, and CD30L and high expression of CD5, whereas state 2 (L14, L28) TCR TAG cells had the opposite pattern ( Fig. 3d ). Consistent with its expression, the Cd38 locus contained intergenic and intronic peaks uniquely accessible in state 2 TST (Extended Data Fig. 8a ). TCF1 downregulation coincided with CD38 upregulation (Extended Data Fig. 8b ), and other key regulators of CD8 T cell differentiation, such as IRF4 and BCL2, showed 
After IL15 in vitro (3 days) a similar binary expression in early and late TST (Extended Data Fig. 8c ). Moreover, TCR TAG cells from FK506 and FK506/TWS119treated mice expressed low CD38 and CD101 compared to controls, correlating with their improved reprogrammability (Extended Data Fig. 7d ). To test whether these markers could identify reprogrammable T cells within a heterogeneous TST population, we sorted CD38 lo CD101 lo and CD38 hi CD101 hi TST from PD1 hi L14 cells and assessed reprogrammability (3 days in vitro IL-15). CD38 lo CD101 lo L14 regained the ability to produce IFNγ and TNFα , but CD38 hi CD101 hi L14 did not ( Fig. 3e ).
We determined whether these findings could be applied to other tumour histologies and/or T cell specificities by using mouse B16F10 (B16) melanoma cells expressing ovalbumin (B16-OVA), a model antigen recognized by OVA-specific OT1 CD8 T cells (TCR OT1 cells). Naive congenically marked TCR OT1 cells were adoptively transferred into B16-OVA tumour-bearing B6 mice. Tumour-infiltrating TCR OT1 cells upregulated CD44, PD1, and LAG3, downregulated CD62L, and lost the ability to produce IFNγ or TNFα (Extended Data Fig. 8d ). At later stages, dysfunctional TCR OT1 cells expressed high levels of CD38 and CD101 and downregulated CD5 compared to early dysfunctional day 5 TCR OT1 cells (Extended Data Fig. 8e ). Moreover, late dysfunctional TCR OT1 cells at day 25 could not regain the ability to produce IFNγ or TNFα , in contrast to early dysfunctional TCR OT1 cells at day 5 (Extended Data Fig. 8f ).
Memory T cells enter state 2 dysfunction in tumours
We next tested whether the 'functionally poised' chromatin state present in memory T cells (M; Fig. 1 ) could prevent them from becoming dysfunctional in tumours. TCR TAG memory cells were transferred into AST-Alb-Cre mice (in which hepatocytes express TAG from birth 6 ) bearing established hepatocellular carcinomas and, one day later, were immunized with LmTAG (Fig. 4a ). By day 7, tumour-infiltrating memory T cells (ML7) rapidly upregulated PD1 and LAG3 and progressively lost effector function ( Fig. 4b , Extended Data Fig. 9a ). ATACseq revealed that M cells followed a similar epigenetic trajectory as the N cells in early malignant lesions ( Fig. 4c , Extended Data Fig. 9b-d ) and remarkably, by day 35, the chromatin state of transferred M cells was nearly identical to that of N at day 35 in early malignant lesions (ML35 and L35; Fig. 4d ). Dysfunctional M cells displayed the same gain and loss of ATAC-seq peaks in critical gene loci including Pdcd1, Ctla4, Cd38, Tcf7, and Ifng (Extended Data Fig. 9e ). Changes in surface protein expression (CD38, CD101, CD30L, and CD5) between ML7 and ML14 were like those seen with N (L7 and L14, respectively) (Extended Data Fig. 9f ). We obtained similar results when LmTAG immunization after adoptive transfer was omitted (Extended Data Fig. 9b-d ).
Chromatin accessibility in human TIL
Finally, we examined chromatin states of human CD8 TIL and peripheral blood lymphocytes from healthy donors. We carried out ATAC-seq on naive (N; CD45RA + CD45RO − ), effector memory (EM; CD45RA − CD45RO + CD62L lo ), and central memory (CM; CD45RA − CD45RO + CD62L hi ) CD8 peripheral blood lymphocytes from healthy donors and PD1 hi CD8 TIL isolated from human melanoma and non-small-cell lung cancer tumours (Extended Data Fig. 10a ). Human N cells had a distinct chromatin state as compared to EM and CM, which were similar (Fig. 5a , Extended Data Fig. 10b ), though distinct accessibility patterns in genes such as SELL (encoding CD62L) distinguished all three states (Extended Data Fig. 10c ). PD1 hi TIL uniquely gained and lost multiple peaks, for example in IFNG, EGR2, CD5, and CTLA4 (Extended Data Fig. 10d ). We compared the non-promoter peak changes that occurred during functional and dysfunctional mouse CD8 T cell differentiation with those observed in human peripheral blood lymphocytes and PD1 hi TIL and found that human PD1 hi TIL had the greatest overlap in peak accessibility changes with dysfunctional (state 2) mouse TST (Fig. 5b) . For example, the TCF7/Tcf7 locus showed similar intergenic and intronic peak accessibility changes in human PD1 hi TIL and mouse state-2 TCR TAG cells (Fig. 5c ). A subset of PD1 hi TIL expressed higher levels of CD38 and CD101 and lower levels of CD5 ( Fig. 5d ), suggesting that these markers could potentially be used to identify T cells that are amenable to therapeutic reprogramming in human tumours.
Discussion
In this study, we define the chromatin state dynamics underlying tumour-specific T cell dysfunction over the course of tumorigenesis. Naive TST encountering tumour antigen in pre-malignant lesions differentiated to an initially plastic, therapeutically reprogrammable chromatin state, then transitioned to a fixed dysfunctional chromatin state that did not undergo further remodelling, even with progression to large established tumours (Extended Data Fig. 10e ). The rapid induction of dysfunction early during tumorigenesis without progression through an effector state resembles peripheral self-tolerance induction 31, 32 . We identified core elements shared between mouse fixed dysfunctional TST and human PD1 hi TIL. Surprisingly, memory TST differentiated to the same fixed dysfunctional chromatin state in tumours, suggesting that antigen exposure in tumours can overwrite pre-existing epigenetic programs regardless of the initial differentiation state.
We identified surface markers, including CD101 and CD38, which were associated with discrete dysfunctional chromatin states and demarcated reprogrammable from non-reprogrammable PD1 hi T cells within heterogeneous TIL populations, a finding of important potential clinical relevance, and human PD1 hi TIL showed heterogeneous expression of these markers. In patients who do not respond to immune checkpoint blockade (non-responders), PD1 hi TIL may be in a fixed dysfunctional state, in contrast to responders whose PD1 hi TIL are in a plastic state, amenable to reprogramming. Our studies on the epigenetic and transcriptional programs underlying TST dysfunctional states and therapeutic reprogrammability point to new targets and strategies to transform TST into potent anti-tumour agents.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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MethOdS
Mice. TCR TAG transgenic mice (B6.Cg-Tg(TcraY1,TcrbY1)416Tev/J) 12 , Cre-ER T2 (B6.129-Gt(ROSA)26Sor tm1(cre/ERT2)Tyj /J), Alb-Cre (B6.Cg-Tg(Alb-cre)21Mgn/J), TCR-OT1 (C57BL/6-Tg(TcraTcrb)1100Mjb/J), Ly5.1 (B6.SJL-Ptprc a Pepc b /BoyJ), and C57BL/6J Thy1.1 mice were purchased from The Jackson Laboratory. TCR TAG mice were crossed to Thy.1.1 mice to generate TCR TAG Thy.1.1 mice. TCR-OT1 were crossed to Ly5.1 mice to generate TCR-OT1 Ly5.1 mice. AST (Albumin-floxStop-SV40 large T antigen (TAG)) 33 were crossed to Cre-ER T2 or Alb-Cre mice to obtain AST-Cre-ER T2 and AST-Alb-Cre mice, respectively 6 . Both female and male mice were used for studies. Mice were age-and sex-matched and between 1.5-3 months old when used for experiments. Animals were assigned randomly to experimental groups. All mice were bred and maintained in the animal facility at Memorial Sloan Kettering Cancer Center (MSKCC). Experiments were performed in compliance with the MSKCC Institutional Animal Care and Use Committee (IACUC) regulations. Antibodies and reagents. Fluorochrome-conjugated antibodies were purchased from BD Biosciences, eBioscience, Biolegend, and Cell Signaling Technology. Tamoxifen (Sigma) stock solution was prepared by warming tamoxifen in 1 ml sterile corn oil at 50 °C for 15 min, then further diluted in corn oil to obtain the stock concentration (5 mg ml −1 in corn oil). A single dose of tamoxifen (1 mg) was administered intraperitoneally (i.p.) into AST-Cre-ER T2 mice. Intracellular cytokine staining. Intracellular cytokine staining was performed using the Cytofix/Cytoperm Plus kit (BD Biosciences) per the manufacturer's instructions. In brief, T cells were mixed with 2 × 10 6 congenically marked splenocytes and incubated with Tag-I peptide (0.5 μ g ml −1 ) or OVA peptide (0.1 μ g ml −1 ) for 4-5 h at 37 °C in the presence of GolgiPlug (brefeldin A). After staining for cell-surface molecules, the cells were fixed, permeabilized, and stained with antibodies against IFNγ (XMG1.2) and TNFα (MP6-XT22). Flow cytometric analysis. Flow cytometric analysis was performed using Fortessa and LSR FACS analysers (BD Biosciences); cells were sorted using BD FACS Aria (BD Biosciences) at the MSKCC Flow Core Facility. Flow data were analysed with FlowJo v. 10 software (Tree Star Inc.). Listeria infection. The Listeria monocytogenes (Lm) Δ actA Δ inlB strain 13 expressing the Tag-I epitope (SAINNYAQKL, SV40 large T antigen 206-215 ) was generated by Aduro Biotech as previously described 34 . Experimental vaccination stocks were prepared by growing bacteria to early stationary phase, washing in phosphate buffered saline, formulated at approximately 1 × 10 10 colony-forming units (c.f.u.) ml −1 , and stored at −80 °C. Mice were infected i.p. with 5 × 10 6 c.f.u. of LmTAG. Adoptive T cell transfer. For the generation of effector and memory TCR TAG CD8 + T cells, 10 5 CD8 + splenocytes from TCR TAG Thy1.1 transgenic mice were adoptively transferred into B6 (Thy1.2) mice; one day later, mice were infected with 5 × 10 6 c.f.u. LmTAG. Effector TCR TAG CD8 + T cells were isolated from the spleens of B6 host mice and analysed 5 or 7 days after LmTAG immunization; memory TCR TAG CD8 + T cells were isolated from spleens of B6 host mice and analysed at least 2-3 months after LmTAG immunization. For the transfer of naive TCR TAG T cells into AST-Cre-ER T2 mice, 1 × 10 5 to 2.5 × 10 6 CD8 + splenocytes from TCR TAG Thy1.1 transgenic mice were adoptively transferred into AST-Cre-ER T2 mice; 1 day later, mice were treated with 1 mg tamoxifen and donor T cells isolated for subsequent analyses. For memory TCR TAG transfer experiments (3-4) × 10 4 TCR TAG Thy1.1 + CD44 hi CD62L hi sorted central memory CD8 T cells were adoptively transferred into AST-Alb-Cre mice; one day later, mice were infected with 5 × 10 6 c.f.u. LmTAG (10 5 central memory T cells were sorted and transferred for experiments without subsequent listeria immunization). B16-OVA tumour model. 5 × 10 5 to 1 × 10 6 B16 tumour cells expressing OVA (full-length or cytosolic as previously described 35 ) were injected into C57BL/6J wild-type mice. Once tumours were established (1-2 weeks later) naive Ly5.1 congenically marked TCR OT1 CD8 T cells were adoptively transferred and isolated from tumours at indicated time points. Tumour volumes did not exceed the permitted volumes specified by the MSKCC IACUC protocol. The B16 cell line was obtained from ATCC. It was tested negative for all rodent pathogens including Mycoplasma pulmonis. Cell isolation for subsequent analyses. Spleens were mechanically disrupted with the back of a 3-ml syringe, filtered through a 70-μ m strainer, and red blood cells were lysed with ammonium chloride potassium buffer. Cells were washed twice with cold RPMI 1640 media supplemented with 2 μ M glutamine, 100 U ml −1 penicillin/streptomycin, and 5-10% FCS (cRPMI). Liver tissue was mechanically disrupted to a single-cell suspension using a 150 μ metal mesh and glass pestle in ice-cold 3% FCS/HBSS and passed through a 70-μ m strainer. The liver homogenate was spun down at 400g for 5 min at 4 °C, and the pellet was resuspended in 30 ml 3% FCS/HBSS, 500 μ l (500 U) heparin, and 17 ml Percoll (GE), mixed by inversion, and spun at 500g for 10 min at 4 °C. Pellet was lysed with ammonium chloride potassium buffer and cells were further processed for downstream applications.
IL-15 in vitro culture. TCR TAG or TCR OTI cells were isolated from tumours at various time points after transfer and cultured in vitro in the presence of IL-15 (100 ng ml −1 ) in cRPMI for 3-4 days. Pharmacologic rescue studies. Naive TCR TAG (Thy1.1 + ) cells were transferred into AST-Cre-ER T2 (Thy1.2 + ) mice which were treated with tamoxifen one day later. On days 2-9, mice were treated with the calcineurin inhibitor FK506 (Prograf, 5 mg ml −1 ) (2.5 mg per kg per mouse i.p. once daily) alone, or in combination with the GSK3β inhibitor TWS119 (Sigma; 0.75 mg per mouse i.p. once daily; days 5-8). Control mice were treated with PBS and/or DMSO. Human samples. Human tumour samples and healthy donor peripheral blood lymphocytes were obtained as per protocols approved by the MSKCC Institutional Review Board (IRB), and all patient and healthy donors provided informed consent. Peripheral blood lymphocytes were flow-sorted for naive, effector memory-like and central memory-like phenotypes as described in Extended Data Fig. 10a . Human melanoma and lung tumours were mechanically disrupted as described for solid tumours in mice, and CD45RO + PD hi CD8 + T cells were flowsorted for subsequent ATAC-seq analysis. Statistical analyses. Statistical analyses on flow cytometric data were performed using unpaired two-tailed Student's t tests (Prism 6.0, GraphPad Software). A P value of < 0.05 was considered statistically significant. Sample preparation for ATAC-seq and RNA-seq. Mouse samples: replicate samples were isolated from spleens or livers and sorted as follows. (i) Naive TCR TAG Thy1.1 + T cells were sorted by flow cytometry (CD8 + CD44 lo ) from spleens of TCR TAG Thy1.1 transgenic mice. (ii) Day 5 and day 7 effector, and memory TCR TAG Thy1.1 + T cells were sorted by flow cytometry (CD8 + Thy1.1 + ) from spleens of infected B6 (Thy1.2) host mice (see above) 5 and 7 days or 2-3 months after listeria infection. (iii) TCR TAG Thy1.1 + T cells from pre/early malignant liver lesions: naive TCR TAG Thy1.1 + T cells were adoptively transferred into AST-Cre-ER T2 mice. 1 day later, mice were given 1 mg tamoxifen i.p. At given time points after tamoxifen treatment, T cells were isolated and sorted (CD8 + Thy1.1 + ) from livers as described above. (iv) TCR TAG Thy1.1 + memory T cells from established hepatocellular carcinomas in AST-Alb-Cre mice: TCR TAG memory T cells were isolated from tumours and flow sorted (CD8 + Thy1.1 + ) as described above.
Human samples: samples were flow-sorted as described in Extended Data Fig. 10a . After flow-sorting, all samples for downstream ATAC-seq analysis were frozen in 10% DMSO/FCS and stored at − 80 °C; samples for RNA-seq were directly sorted into Trizol and frozen and stored at − 80 °C. Transcriptome sequencing. RNA from sorted cells was extracted using RNeasy mini kit (Qiagen) as per instructions provided by the manufacturer. After ribogreen quantification and quality control of Agilent BioAnalyzer, 6-15 ng of total RNA was amplified (12 cycles) using the SMART-seq V4 (Clontech) ultralow input RNA kit for sequencing. 10 ng of amplified cDNA was used to prepare Illumina hiseq libraries with the Kapa DNA library preparation chemistry (Kapa Biosystems) using 8 cycles of PCR. Samples were barcoded and run on a Hiseq 2500 1T in a 50 bp/50 bp Paired end run, using the TruSeq SBS Kit v3 (Illumina). An average of 51 million paired reads were generated per sample and the percent of mRNA bases was 62.5% on average. ATAC sequencing. Chromatin profiling was performed by ATAC-seq as described previously 11 . In brief, 12,000 to 50,000 cells were washed in cold PBS and lysed. Transposition was performed at 42 °C for 45 min. After purification of the DNA with the MinElute PCR purification kit (Qiagen), material was amplified for 5 cycles. Additional PCR cycles were evaluated by real time PCR. Final product was cleaned by Ampure Beads at a 1.5× ratio. Libraries were sequenced on a Hiseq 2500 1T in a 50 bp/50 bp Paired end run, using the TruSeq SBS Kit v3 (Illumina). An average of 47 × 10 6 paired reads was generated per sample. ATAC data and preprocessing. Raw ATAC-seq reads were trimmed and filtered for quality using Trim Galore! v0.4.0 (http://www.bioinformatics.babraham.ac.uk/ projects/trim_galore/), powered by CutAdapt v1.8.1 (http://dx.doi.org/10.14806/ ej.17.1.200) and FastQC v0.11.3 (http://www.bioinformatics.babraham.ac.uk/ projects/fastqc/). Paired-end reads were aligned using Bowtie2 v2.2.5 (ref. 36) against either mm10 or hg38 and non-uniquely mapping reads were removed. To correct for the fact that the Tn5 transposase binds as a dimer and inserts two adapters in the Tn5 tagmentation step 37 , all positive-strand reads were shifted 4 bp downstream and all negative-strand reads were shifted 5 bp upstream to centre the reads on the transposon binding event 11 . We then pooled the shifted reads by sample type and identified peaks using MACS2 (ref. 38 ) with a threshold of FDR-corrected P < 1 × 10 −2 using the Benjamini-Hochberg procedure for multiple hypothesis correction. As called peaks may be caused by noise in the assay and not reflect true chromatin accessibility, we calculated an irreproducible discovery rate (IDR) 39 for all pairs of replicates across a cell type. The IDR is an estimate of the threshold where two ranked lists of results, in this case peak calls ranked by P value, no longer represent reproducible events. Using this measure, we excluded peaks Article reSeArcH that were not reproducible (IDR < 5 × 10 −3 ) across at least one pair of replicates in each mouse or human cell type. ATAC-seq atlas creation. Peaks found reproducibly in each mouse cell type were combined to create a genome-wide atlas of accessible chromatin regions. Reproducible peaks from different samples were merged if they overlapped by more than 75%. To create the atlas of accessible peaks for the human samples, reproducible peaks from the normal human cell types (HN, HCM, and HEM) and the tumour-derived cells (PD1 hi ) were combined. There was greater variation between the human TIL samples than between T cell samples from healthy donors; this led to fewer reproducible peaks being called in the TIL samples. Like the mouse atlas, peaks overlapping by more than 75% were merged in the human atlas. Numbers of called peaks and reproducible peaks for each sample type are listed in Supplementary Data. Assignment of ATAC-seq peaks to genes. The RefSeq transcript annotations of the hg38 version of the human genome and the mm10 version of the mouse genome were used to define the genomic location of transcription units. For genes with multiple gene models, the longest transcription unit was used for the gene locus definition. ATAC peaks located in the body of the transcription unit, together with the 2-kb regions upstream of the TSS and downstream of the 3′ end, were assigned to the gene. If a peak was found in the overlap of the transcription units of two genes, one of the genes was chosen arbitrarily. Intergenic peaks were assigned to the gene with a TSS or 3′ end that was closest to the peak. In this way, each peak was unambiguously assigned to one gene. Peaks were annotated as promoter peaks if they were within 2 kb of a transcription start site. Non-promoter peaks were annotated as intergenic, intronic or exonic according to the relevant RefSeq transcript annotation. ATAC-seq peak atlas summary. We found a total of 75,689 reproducible ATACseq peaks in the mouse samples. Examining genomic locations, 39.6% of the peaks were found in introns, 36.3% were found in intergenic regions, 22.1% were found in promoters and 2.1% were found in exons. In the human samples, we found a total of 42,104 reproducible ATAC-seq peaks. Among these peaks, 34.0% were found in introns, 29.9% were found in intergenic regions, 34.0% were found in promoters, and 2.0% were found in exons. Chromosome-wide genomic coverage for all (autosomal) chromosomes and all samples was examined and no systemic bias was observed. Principal component analysis. PCA plots were generated using read counts against all mouse or human atlas peaks. These read counts were processed using the variance-stabilizing transformation built into the DESeq2 package 40 . Differential peak accessibility. Reads aligning to atlas peak regions were counted using the summarizeOverlaps function of the R packages GenomicAlignments v1.2.2 and GenomicRanges v1. 18.4 (ref. 41) . Differential accessibility of these peaks was then calculated for all pairwise comparisons of cell types using DESeq2 v1.6.3 (ref. 40 ). Peak heat maps and genome coverage plots. The ATAC-seq peak heat maps were created by pooling the DESeq size-factor normalized read counts per atlas peak across replicates of ATAC-seq data and binning the region ± 1 kb around the peak summit in 20 bp bins. To improve visibility, bins with read counts greater than the 75th percentile + 1.5 × IQR were capped at that value. All analysis was performed using the original uncapped read counts. Genome coverage plots were generated for each replicate of ATAC-seq and RNA-seq by calculating genome-wide coverage of aligned reads using the bedtools function genomecov 42 . For ATAC-seq samples, this coverage was calculated after shifting the reads to account for the Tn5induced bias. The coverage values were then normalized using DESeq2-derived size factors and replicates were combined to create one signal track for each sample type. ATAC-seq and RNA-seq coverage plots were generated using the Integrated Genomics Viewer (Broad) 43 . Transcription factor peak assignment. Using the MEME 44 -curated CisBP 45 transcription factor binding motif (TFBM) reference, we scanned the mouse ATACseq peak atlas with FIMO 46 to find peaks likely to contain each TFBM (P < 10 −4 ). The MEME cisBP reference for direct and inferred motifs for Mus musculus was curated by the MEME suite developers as follows: to reduce redundancy, for each transcription factor a single motif was selected according to the following precedence rules. The direct motif was chosen if there was one, otherwise the inferred motif with the highest DNA binding domain (DBD) similarity (according to CisBP) to a transcription factor in another species with a direct motif was chosen. If there was more than one direct motif or inferred motif with the highest DBD similarity, a motif was chosen according to its provenance (CisBP 'Motif_ Type' attribute) in the following order: ChIP-seq, HocoMoco, DeBoer11, PBM, SELEX, B1H, High-throughput Selex CAGE, PBM:CSA:DIP-chip, ChIP-chip, COMPILED, DNaseI footprinting. Each motif thus determined was linked to a single transcription factor in the CisBP database, following the same precedence rules. The final reference contained 718 motifs between 6 and 30 bp in width (average width, 10.7 bp). Transcription factors with similar FIMO-predicted target peaks were combined into transcription factor families. Similarity of predicted target peak sets was measured using the Jaccard index (size of intersection/size of union). Transcription factors with Jaccard indices greater than 0.7 were combined for further analyses. Relative transcription factor accessibility was calculated using two one-sided Wilcoxon rank-sign tests comparing the distributions of peak heights for peaks containing FIMO-predicted transcription factor binding sites. Peak height was defined as the maximum observed number of reads overlapping at any point in the defined peak region. Footprinting analysis. ATAC-seq footprints containing FIMO-predicted transcription factor binding sites (P < 1 × 10 −4 ) were selected. Positive-and negative-strand ATAC-seq cut sites were counted 100 bp up-and down-stream of the centre of the motif site in each of the selected peaks. The mean number of ATAC-seq cut sites across matching atlas peaks was then plotted to generate the footprint figures. Diamond plots. In these plots, each gene is represented by a stack of diamonds corresponding accessible chromatin regions of the same gene. The bottom-most peak in this stack corresponds to the log 2 fold change in expression of the gene. The diamonds are coloured according to the accessibility change of their ATACseq peak with blue indicating closing and red indicating opening. The colour scale was based on the rank-order of the peak accessibility changes. In Extended Data Fig. 6d , the colour scale ranges from a log 2 fold change of − 3.92 to 4.96 (L14/L7). Comparison of human and mouse ATAC-seq atlases. The UCSC liftOver tool 47 was used to convert the mouse ATAC-seq peak atlas from mm10 coordinates to hg38 coordinates. The converted mouse atlas was then compared to the human atlas and 20,642 mouse peaks were within 100 bp of a human peak. We compared the results from the UCSC liftover tool and an alternative method, bnMapper 48 , and confirmed that the set of peaks mapped by bnMapper and by the UCSC lift-Over tool was nearly identical (57,383 out of 75,689 by liftOver and 58,299 out of 75,689 by bnMapper). Additionally, all 57,223 peaks mapped to hg38 by both tools were mapped to the same chromosomal positions. The majority of these conserved peaks were found in promoter regions (56.4%), whereas relatively fewer were found in intergenic (22.4%), intronic (19.6%), and exonic (1.5%) regions. For non-promoter peaks conserved between human and mouse, Spearman correlations of log 2 (FC) were calculated between human N and human EM, CM or PD1 hi TIL versus log 2 (FC) between mouse N and functional E5, E7, M and dysfunctional L5 to L60. RNA-seq. Raw ATAC-seq reads were trimmed and filtered for quality using Trim Galore! v0.4.0 (http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/), powered by CutAdapt v1.8.1 (http://dx.doi.org/10.14806/ej.17.1.200) and FastQC v0.11.3 (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Paired-end reads were aligned using STAR 49 against either mm10 or hg38. The RefSeq transcript annotations of the hg38 version of the human genome and the mm10 version of the mouse genome were used for the genomic location of transcription units. Reads aligning to annotated exon regions were counted using the summarizeOverlaps function of the R packages GenomicAlignments v1.2.2 and GenomicRanges v1. 18.4 (ref. 41) . Differential expression of genes across cell types was calculated using DESeq2 v1. 6.3 (ref. 40) . FDR correction of 0.05 was imposed unless otherwise stated. A log 2 fold change cutoff of 1 was used in some analyses as indicated. Pathway analysis. Enrichment of gene ontology terms in sets of ATAC-seq peaks was calculated using GREAT (Genomic Regions Enrichment of Annotations Tool) using default parameters 50 . The full ATAC-seq atlas was used as the background set. Membrane protein analysis. To identify membrane proteins that distinguished early (L5-L7) from late (L14-L60) dysfunctional TST, RNA-seq data was analysed for genes contained within the gene ontology category 0016020 (membrane proteins). The top 50 most up-and downregulated genes (size-factor normalized RPKM) when compared between L5-L7 and L14-L60 were plotted in a heat map (row-normalized). Protein expression was assessed by flow cytometry for those membrane proteins for which monoclonal antibodies were available. Mouse targets (clone; supplier): CD5 (53-7.3; eBioscience), CD30L (RM153; eBioscience), CD38 (90; Biolegend), and CD101 (Moushi101; eBioscience). Human targets: CD5 (L17F12; Biolegend), CD38 (HB7; eBioscience), CD101 (BB27; Biolegend). Data reporting. No statistical methods were used to predetermine sample size. The investigators were not blinded to allocation during experiments and outcome assessment. Mice or human samples were excluded if donor or tumour-infiltrating CD8 T cells could not be found. Data availability. All data generated and supporting the findings of this study are available within the paper. The RNA-seq and ATAC-seq data have been deposited in the Gene Expression Omnibus (GEO Super-Series accession number GSE89309 (GSE89307 for RNA-seq, GSE89308 for ATAC-seq). Source Data for Figs 1-5 and Extended Data Figs 1, 3, and 7 are provided with the online version of the paper. Additional information and materials will be made available upon request.
